Results for narkolepsiaga translation from Estonian to English

2raporteeritud narkolepsiaga patsientidel ajutise vaktsineerimisjärgse nähuna.
2reported in patients with narcolepsy and as a temporary event following vaccination

see on narkolepsiaga patsientide hindamise standardskaala väärtustega vahemikus 0–24.
this is a standard scale used in patients with narcolepsy which ranges from 0 to 24.

wakixit uuriti 2 põhiuuringus, kus osales 261 narkolepsiaga täiskasvanut, kellest enamikul oli ka katapleksia.
wakix has been investigated in 2 main studies involving a total of 261 adults with narcolepsy, the majority of whom also had cataplexy.

et narkolepsiaga patsientide arv on väike ja see haigus esineb harva, nimetati wakix 10. juulil 2007 harvikravimiks.
because the number of patients with narcolepsy is low, the disease is considered ‘rare’, and wakix was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 10 july 2007.

naatriumoksübaat on kesknärvisüsteemi depressant, mis vähendab päevast unisust ja katapleksiat narkolepsiaga patsientidel ja muudab une struktuuri vähendades fragmenteeritud öist und.
sodium oxybate is a central nervous system depressant which reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy and modifies sleep architecture reducing fragmented nighttime sleep.

pitolisanti platseeboga võrrelnud kaksikpime randomiseeritud paralleelrühmadega keskne uuring harmony ctp oli üles ehitatud hindama pitolisandi efektiivsust narkolepsiaga patsientidel, kellel esineb sageli katapleksiat.
harmony ctp, a supportive double blind, randomized, parallel group study of pitolisant versus placebo, was designed to establish pitolisant efficacy in patients with high frequency cataplexy in narcolepsy.

uuring hõlmas 105 narkolepsiaga patsienti, kellel uuringu alguses oli suur katapleksiahoogude nädalane esinemissagedus (54 patsienti said raviks pitolisanti ja 51 platseebot).
105 narcoleptic patients with high frequency weekly cataplexy rates at baseline were included (54 patients treated with pitolisant and 51 with placebo).

enne naatriumoksübaadi annuse suurendamist (vt lõik 4.2) peaksid arstid teadma, et narkolepsiaga patsientidest kuni ligikaudu 50%-l esineb uneapnoe.
before increasing the sodium oxybate dose (see section 4.2), prescribers should be aware that sleep apnoea occurs in up to 50% of patients with narcolepsy.

2005. aasta juunis soovitas euroopa ravimihindamisameti (emea) inimtervishoius kasutatavate ravimite komitee (chmp) anda müügiluba ravimile xyrem (mille toimeaineks on ghb), et kasutada seda narkolepsiaga täisealiste patsientide katapleksiaraviks (emea, 2005) (139).
in june 2005, the committee for medicinal products for human use (chmp) of emea recommended granting a marketing authorisation for the medicinal product xyrem (ghb being the active substance) for the treatment of cataplexy in adult patients with narcolepsy (emea, 2005) (139).